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Abstract
Background:  Spinal muscular atrophy (SMA) represents the second most common fatal
autosomal recessive disorder after cystic fibrosis. Due to the high carrier frequency, the burden of
this genetic disorder is very heavy in developing countries like India. As there is no cure or effective
treatment, genetic counseling becomes very important in disease management. SMN1 dosage
analysis results can be utilized for identifying carriers before offering prenatal diagnosis in the
context of genetic counseling.
Methods: In the present study we analyzed the carrier status of parents and sibs of proven SMA
patients. In addition, SMN1 copy number was determined in suspected SMA patients and parents
of children with a clinical diagnosis of SMA.
Results: wenty nine DNA samples were analyzed by quantitative PCR to determine the number
of SMN1 gene copies present, and 17 of these were found to have one SMN1 gene copy. The
parents of confirmed SMA patients were found to be obligate carriers of the disease. Dosage
analysis was useful in ruling out clinical suspicion of SMA in four patients. In a family with history of
a deceased floppy infant and two abortions, both parents were found to be carriers of SMA and
prenatal diagnosis could be offered in future pregnancies.
Conclusion: SMN1 copy number analysis is an important parameter for identification of couples
at risk for having a child affected with SMA and reduces unwarranted prenatal diagnosis for SMA.
The dosage analysis is also useful for the counseling of clinically suspected SMA with a negative
diagnostic SMA test.
Background
With a prevalence of 1 in 10,000 live births and a carrier
frequency of approximately 1 in 50 [1], proximal spinal
muscular atrophy (SMA) represents the second most com-
mon fatal autosomal recessive disorder after cystic fibrosis
[2]. SMA is characterized by the degeneration of anterior
horn cells of the spinal cord, resulting in progressive
weakness. The condition is clinically heterogeneous and
has been divided into four subtypes according to age of
onset and clinical severity [3]. Molecular genetic analysis
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has mapped all four forms of childhood and adult SMA to
chromosome 5q11.2-q13.3, suggesting that they are
allelic disorders.
In a majority of normal individuals in the population, sur-
vival motor neuron (SMN) genes are present in at least
one telomeric (SMN1) and one centromeric (SMN2) copy
per chromosome. However, 26% of all normal chromo-
somes 5 lack SMN2 copy of the gene. The two SMN genes
are highly homologous but a single nucleotide variation
in exon 7 of SMN1 and SMN2 genes is responsible for
functional differences [4]. The majority of SMA patients,
irrespective of their clinical types, have homozygous dele-
tion of the SMN1 gene [5]. In addition intragenic muta-
tions have been identified in most of the patients who
have only one copy of SMN1  gene, confirming the
involvement of SMN1 in the pathogenesis of SMA [6].
Normal individuals with one copy of the SMN1 gene are
carriers for this autosomal recessive disorder.
The single nucleotide differences in exons 7 and 8 are used
to distinguish SMN1 and SMN2 in diagnostic and prena-
tal testing for SMA [7,8]. Although this methodology can
detect homozygous absence of SMN1, it cannot differen-
tiate the presence of one copy from two or more copies of
SMN1. In recent years, molecular diagnostic testing for
SMN1 copy number by dosage analysis has been devel-
oped [9,10], and is used to determine the carrier status for
SMA in the majority of cases. However, in 3.7% of carriers,
referred as "2+0" carriers, two copies of the SMN1 gene are
present on one chromosome 5 and a deletion of SMN1
allele is present on the other chromosome 5 [11]. This sit-
uation cannot be distinguished by dosage analysis alone.
In such cases dosage analysis in combination with linkage
analysis for extended family members may be required to
unequivocally determine whether an individual is "2+0"
(a carrier) or "1+1" (not a carrier) [10].
Due to high carrier frequency, the burden of this genetic
disorder is very heavy and genetic counseling is an active
component in the disease management. In many cases the
index patient dies without proper clinical diagnosis due to
limited facilities and lack of awareness in primary care
providers in India [12]. Therefore, carrier testing is partic-
ularly useful to direct genetic counseling for prenatal diag-
nosis. This is the first study from India using testing for the
carrier status of parents and sibs of patients with a proven
diagnosis of SMA. Additionally, SMA carrier testing has
been performed for suspected SMA patients and parents
of children clinically suspected to have SMA.
Methods
Subjects
Detailed clinical history and pedigree was drawn for all
the cases and their families. Clinical examinations of
patients (if alive) and family members were carried out in
the Genetics Outpatient Department at Sanjay Gandhi
Post Graduate Institute of Medical Sciences. Informed
consents were obtained from all study members following
genetic counseling. Twenty-nine individuals included in
the study were divided into three categories. Group I com-
prised 14 parents and sibs of SMN1 gene deletion positive
cases. Group II comprised 10 individuals, four couples,
and two sibs whose deceased child (or children) or sibs
were suspected to have SMA. Group III comprised 5
patients with a strong clinical suspicion of SMA but did
not show homozygous deletions of exons 7 and 8 of the
SMN1 gene. Five ml blood was collected in EDTA tubes
from all individuals enrolled in the study.
DNA isolation and PCR
DNA was extracted from blood samples using DNA extrac-
tion kit (Qiagen, Germany) according to the manufac-
turer's instructions. Patients were tested for homozygous
deletion of exons 7 and 8 of SMN1 gene by a Polymerase
Chain Reaction-Restriction Fragment Length Polymor-
phism (PCR-RFLP) method as described previously [13].
SMN1 copy number assay
The SMA carrier test determines the SMN1  gene copy
number by comparing the levels of amplified products
generated from exon 7 of SMN1 and a two-copy control
gene following PCR amplification. Multiplex PCR of exon
7  SMN1  genomic sequences, CFTR  exon 4 genomic
sequences, and modified SMN1 and CFTR internal stand-
ard (IS) was performed using hexachloroflorescein
labeled primers. Primer sequences and PCR amplification
conditions were according to McAndrew et al (1997) [9]
and Chen et al (1999) [10]. Briefly, PCR was performed in
a 50 µl reaction mix containing 10 mM Tris-HCl (pH-8.3)
PCR buffer, 1.5 mM MgCl2, 50 mM KCl, 0.01% (w/v) gel-
atin (Applied BioSystems Inc., (ABI) CA, USA), 1 mM
spermidine, 0.05 mM each primer, 400 mM each dNTP, 1
unit Ampli Taq Polymerase (ABI) and 200 ng of genomic
DNA. Internal Standards at approximately equimolar con-
centration to the genomic templates (6.4 × 104 copies)
were added to each reaction tube. PCR amplification con-
ditions were as follows: initial denaturation at 95°C for 5
min followed by 22 cycles of denaturation for 30 sec at
95°C, annealing for 30 s at 55°C, and elongation for 2
min at 72°C, followed by a final extension step for 10 min
at 72°C. Each patient sample was analyzed in duplicate,
and controls included 5 known two-copy, a one-copy and
a homozygous deleted DNA samples, as well as water (no
DNA template control).
After PCR, 4 µl of amplified DNA from each reaction was
digested in a 6 µl reaction volume with 1 unit of Dra I
(New England Biolabs, USA) for 3 hours at 37°C. Two µl
of the Dra I digestion were mixed with 4 µl of formamide,BMC Medical Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2350/6/22
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0.5 µl of Gene Scan-500 Rox (ABI) and 0.5 µl of loading
buffer, heated at 95°C for 5 min and then placed on ice
for 2 min. Digested PCR product mixtures were analyzed
on an ABI 373 Genetic Analyzer instrument (ABI). Peak
areas of the various products were determined using ABI
Gene Scan 672 Software (ABI).
The SMN1 copy number was calculated using peak areas
as follows: (SMN1 genomic/SMN1-IS) / (CFTR genomic/
CFTR-IS). Ratios were then normalized to the mean of five
control samples with two copies of SMN1 gene.
Results
Fig 1 shows the pedigree for Case 3 (Fig 1A), results of
PCR-RFLP for exons 7 (Fig 1B) and 8 (Fig 1C) of SMN1
gene, and SMN1 dosage analysis gel scans (Fig 1D). The
index patient had homozygous deletion of both exons 7
and 8 of SMN1 gene as shown by the absence of 188 bp
and 187 bp bands, respectively (Fig. 1B and 1C, lanes 2
and 2, respectively). Dosage analysis gel scans of the
father, mother, and sib are shown with band sizes (in base
pairs) and peak areas under each peak (Fig 1D). The
number of SMN1 gene copies was calculated as described
in Methods. Normalized results (the mean of five control
samples with two copies of the SMN1 gene) were consist-
ently within the ranges of 0.8–1.2 for normal controls
with two copies of SMN1 gene.
Fourteen samples in Group I (Cases 1–6) were from the
parents and sibs of SMA patients with homozygous dele-
tion of both exons 7 and 8 of SMN1 gene. Out of these, all
parents and three of the four sibs had one SMN1 gene
copy and one sib had two SMN1 gene copies (Table 1). In
Group II (Cases 7–10), carrier analysis was performed on
the basis of family history of SMA. In this group, five par-
ents had two SMN1 copies (Cases 7, 8, 9) and three par-
ents had one SMN1 gene copy (Case 9 and 10). Case 10
had two children and they showed two copies of SMN1
gene, respectively (Table 1). Five samples in Group III
were analyzed to determine the copy number of SMN1
gene as these patients had strong clinical features consist-
ent with SMA but did not have homozygous deletion of
exons 7 and 8 of the SMN1 gene. Out of these, only a sin-
gle patient had one copy of SMN1 gene, and the remain-
ing four cases had two copies of SMN1 gene (Data not
shown).
Discussion
Twenty-nine samples were analyzed by quantitative PCR
to determine the number of SMN1 gene copies present,
and 17 of these were found to have one SMN1 gene copy.
In the previous study, it was reported that 94.3% of nor-
mal individuals had two SMN1 copies and 2.1%, 0.7%
and 2.9% had three, four and one copy, respectively [14].
Only one SMN1 gene copy is sufficient for normal func-
tioning in an individual, as all parents with one copy of
the SMN1 gene are asymptomatic.
From our small group of SMA cases, parents of confirmed
SMA patients were obligate carriers of the disease and this
was confirmed by SMA carrier testing. However, parents of
children with SMA may not always be carriers as de-novo
deletions of the SMN1 gene occurs in more than 2% of
patients, with SMA [10,15]. Presence of de-novo deletion
in the family lowers the recurrence risk for the couples
from 25% to the risk of a second de-novo mutation which
is very low. Knowledge of the carrier status of parents of
affected children is useful for determining if a de-novo
mutation has occurred and establishing the couple's
future risk of having an affected child. If the parents are
found to be carriers, then carrier testing can be offered to
the siblings of the parents, who have a 50% risk of also
being a carrier for SMA [1].
It has been reported that a small proportion of parents
may have a "2+0" genotype in which there are two SMN1
gene copies on one chromosome and none on the other.
In such cases a normal dosage analysis should be followed
by linkage analysis of the family in order to try to distin-
guish between individuals who carry one SMN1 gene on
each chromosome and those with a two-copy allele [1].
The recurrence risk for the family in which the "2+0" gen-
otype is present is 25%.
Copy number analysis is also useful for testing of patients
with a clinical diagnosis of SMA who are negative by a
SMA diagnostic test that looks for homozygous deletion
of exon 7 and 8 of the SMN1 gene. SMA is one of a wide
spectrum of muscle and nerve disorders such as Becker
muscular dystrophy, myotonic dystrophy, and Charcot-
Marie tooth disease (Type IA) [16] that affect infants and
young children. Clinical symptoms among these disor-
ders are overlapping and may not be sufficiently specific
to make a reliable clinical diagnosis of SMA. Patients that
are referred for molecular genetic testing generally have
symptoms, like hypotonia, floppiness, proximal muscle
weakness, and loss of ambulation. These symptoms are
not specific to 5q-linked SMA and in infants there are
additional complications. In such circumstances molecu-
lar genetic testing for SMA is the best method to confirm
the clinical diagnosis [17,18]. Muscle testing (EMG exam-
ination) at times may be difficult to perform in a neonate.
Homozygous deletion of the SMN1  gene confirms the
diagnosis of 5q-linked SMA. If no homozygous deletion is
detected, then SMN1 copy number analysis may be used
if there is a strong clinical suspicion of SMA, since there is
a 1 in 50 carrier frequency in the general population. An
individual with signs and symptoms suggestive of SMA
who does not lack at least one copy of the SMN1 gene isBMC Medical Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2350/6/22
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SMN1 copy number analysis for the family of Case 3 Figure 1
SMN1 copy number analysis for the family of Case 3. 1A The pedigree of the family of Case 3. 1B: Exon 7 PCR-RFLP Polyacr-
ylamide gels showing the undigested and digested products of SMN exon 7 after Dra I digestion. Lane 1, undigested product of 
patient; Lane 2, digested product of patient with SMN1 deletion; Lane 3, undigested product of sibling; Lane 4, digested product 
of sibling with no SMN1 deletion. 1C: Exon 8 PCR-RFLP after Dde I digestion. Lanes 1 and 3, undigested PCR product; Lane 2, 
digested product of patient with homozygous deletion of exon 8 of the SMN1 gene; Lane 4, digested product of sibling with no 
homozygous deletion of SMN1. 1D Quantitative PCR gel scans of Father (I: 1), Mother (I: 2) and sibling (II: 4). Band sizes in 
base pairs are shown in the upper boxes and peak areas in the lower boxes. IS, internal standards.
I:1 I:2
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less likely to have 5q-linked SMA. For example, in the
Group III patients, four of five had two copies of SMN1
gene and therefore were unlikely to have 5q-linked SMA.
In such situations, the possibility of related disorders
other then 5q-linked SMA should be considered. How-
ever, in patients with one copy of the SMN1 gene, the
chances of a non-deletion type of mutation in the other
allele may be explored [1,6].
The most severe form of SMA occurs at birth or in early
infancy and may be difficult for primary care providers in
India to diagnose. No data are available on the popula-
tion prevalence of SMA and the status of diagnosis of SMA
from India, due to the limited number of centers and the
high cost and complexity of the molecular genetic test. So
in many cases the child usually expires before the diagno-
sis is confirmed and the parents approach with a history
of a previous child's death with symptoms consistent with
SMA. In absence of a sample for molecular genetic testing
for SMA, the information obtained by SMN1  copy
number analysis for the parents can be utilized to confirm
the diagnosis for the deceased child and to offer prenatal
diagnosis for future pregnancies. The presence of one copy
of the SMN1 gene in the parents will confirm their carrier
status and prenatal diagnosis can be clearly advised in
subsequent pregnancies. The family in case 10 had a his-
tory of a deceased floppy infant and two abortions. No
surviving affected child was available. After SMN1 copy
number analysis, both parents were found to have one
SMN1 copy of the gene. Prenatal diagnosis was offered to
the family and the fetus was found to be normal. Another
child was born in the family and he was normal and dos-
age analysis showed two copies of SMN1 gene.
If both parents have two or more copies of SMN1 gene, as
for the parents of Cases 7 and 8, then prenatal diagnosis
for SMA will not be useful for future pregnancies. How-
ever, if only one of the parents has one SMN1 copy, as was
seen in Case 9, then additional testing could be performed
to clarify whether the two-copy parent is 1+1 or 2+0 using
carrier testing and linkage analysis of additional family
members. If the two-copy parent is 2+0, then prenatal
diagnosis using the diagnostic test is still useful. If the two-
copy parent is 1+1, then the affected child will usually
have one SMN1 copy, and dosage analysis can be used for
prenatal diagnosis, with a two-copy result indicating the
fetus will not be affected. If the fetus has one SMN1 copy,
then linkage analysis can be used, if DNA is available from
an affected child. If only one parent has one copy of
SMN1 gene, the situation may be clearly discussed with
the parents before any prenatal testing is considered.
Conclusion
Our results confirm that SMN1 copy number analysis is
an important parameter for identification of couples at
risk for having a child affected with SMA and reduces
unwarranted prenatal diagnosis for SMA. Copy number
analysis is also useful in the setting of clinically suspected
SMA with a negative diagnostic SMA test.
Table 1: Copy number of SMN1 gene in parents, sibs and SMA 
patients
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